MedTrace Logo

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

NCT03392051 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-04-05

No results posted yet for this study

Summary

This is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of multiple doses of clopidogrel

Conditions

Interventions

DRUG

ISIS 681257

Xmg dose administered as a subcutaneous injection

DRUG

Clopidogrel

75mg tablet administered orally

Sponsors & Collaborators

  • Akcea Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-28
Primary Completion
2018-03-18
Completion
2018-03-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03392051 on ClinicalTrials.gov